Risk-reducing medication for primary breast cancer: A network meta-analysis

Simone Mocellin, Annabel Goodwin, Sandro Pasquali

Research output: Contribution to journalReview article

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the efficacy and acceptability of single agent CPAs for the prevention of primary breast cancer, in unaffected women, at an above average risk of developing breast cancer. Using a network meta-analysis, we also intend to rank single CPAs, based on their efficacy and acceptability (an endpoint that is defined as the inverse of CPA-related toxicity).

Original languageEnglish
Article numberCD012191
JournalCochrane Database of Systematic Reviews
Volume2016
Issue number5
DOIs
Publication statusPublished - May 13 2016

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Risk-reducing medication for primary breast cancer: A network meta-analysis'. Together they form a unique fingerprint.

  • Cite this